Skip to main content

Table 1 Clinicopathological Subtypes and Clinical Decision-Making [Ref [5]

From: Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI

Clinicopathological Subtype IHC status Clinical Decision-Making
Luminal A ER and/or PR positive
HER2 negative
Ki-67 low (< 14%)
Endocrine therapy
aLuminal BHER2- ER and/or PR positive
HER2 negative
Ki-67 high
Endocrine±cytotoxic therapy
bLuminal BHER2+ ER and/or PR positive
any Ki-67
HER2 over-expressed
Cytotoxics + anti-HER2 + endocrine therapy
HER2 positive HER2 over-expressed Cytotoxics + anti-HER2
Triple negative ER and PR absent
HER2 negative
Cytotoxics
  1. aLuminal BHER2- luminal B/HER2 negative, bLuminal BHER2+ luminal B/HER2 positive, IHC immunohistochemistry
\